TrialMolecular genetics & genomic medicine2025

Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.

Dominique P Germain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.